New kidney drug QRX-3 shows promise in slowing disease progression
NCT ID NCT06948292
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This completed Phase 2 trial tested QRX-3, a drug that boosts NAD activity in kidney cells to reduce damage and improve function. 127 adults with chronic kidney disease stages 3-5 took part over 12 months. Researchers measured changes in kidney function and protein levels in urine to see if QRX-3 slows disease worsening compared to no treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- QRX-3
- What this could lead to
- If successful, QRX-3 could offer a new way to slow kidney function decline in chronic kidney disease patients, potentially delaying the need for dialysis or transplant.
- What could go wrong
- This is a Phase 2 trial with 127 participants, so results are preliminary. The drug may not show significant benefit over placebo, and long-term safety is not yet established.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
127 people
The number who actually took part.
- Started
-
Mar 2023
- Finished
-
Oct 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient with Chronic kidney disease stage 3-5 * Estimated Glomerular function by MDRD of less than 60mls/min * Patients with declining renal function ( as measured by eGFR by MDRD ) * Rate of decline of eGFR over the last one year of less than 20% * Negative Serology markers for CKD etiology * Provider perceived adherence to study follow- up Exclusion Criteria: * Rapid rate of decline in kidney function of \> 10 % over 3 months * Symptomatic renal failure * Presence of any suspected Acute renal failure superimposed * Presence of cast , hematuria, or abnormal urinalysis outside of simple UTI * No known reversible cause of renal decline
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic kidney disease stages 3-5 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Neukidney Inc
Pasedena, Texas, 77504, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Patient's own kidney cells hold off dialysis?
- 12,000 diabetes records put kidney risk under the microscope
- A simple blood ratio may predict diabetic kidney disease
- Can a Patient's own kidney cells slow kidney disease?
- Can we predict kidney damage in young diabetics before it starts?
- A blood test that could spot kidney trouble in diabetes?